SLC22A2 and neoplasm: The current study demonstrates that our proposed Que-PEG-PCL effectively mitigate DDP-induced nephrotoxicity while simultaneously enhancing its antitumor efficacy through a dual mechanism involving inhibition of OCT2-mediated renal uptake and potentiation of ROS-dependent apoptosis in tumor cells.